DEDouglas F. Easton

Douglas F. Easton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Douglas F. Easton has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Towards a public-facing version of the CanRisk tool: Co-designing, developing and evaluating MyCanRisk

    by Cameron Wilson, Francisca Stutzin Donoso, Juliet A. Usher-Smith, Nichola Fennell, Lorenzo Ficorella, Fiona M. Walter, Jon Emery, Douglas F. Easton, Marc Tischkowitz, Antonis C. Antoniou, et al.

    The CanRisk tool allows healthcare professionals to calculate validated multifactorial estimates of breast, ovarian, and prostate cancer risk. To support patient involvement in risk assessment, we co-designed a public-facing tool, MyCanRisk, which allows patients to collect and share risk information in advance of a clinical appointment, without generating risk estimates. This study describes the user-centred development of MyCanRisk and its initial evaluation. Development involved co-design workshops with patients, public contributors, healthcare professionals, and researchers, followed by iterative accessibility and usability testing against WCAG 2.2. Evaluation used a multi-methods design: 51 women with a family history of breast cancer completed MyCanRisk and, approximately two weeks later, a structured clinical-style interview. Agreement in risk categorisation was assessed using Cohen’s kappa. Semi-structured interviews with a purposive subsample (n=15) explored user experiences. MyCanRisk was perceived as accessible and easy to use. Agreement between MyCanRisk and structured interviews for risk categorisation was substantial (κ = 0.81, 95% CI 0.65–0.97). Discrepancies mainly reflected difficulties recalling detailed family history, such as ages at diagnosis and dates of birth/death. Participants valued the stepwise flow and asynchronous completion but reported challenges when their knowledge was incomplete. Suggested improvements included options to record approximate or unknown data and greater flexibility to update submissions. MyCanRisk has the potential to reduce data collection burden during clinical encounters, support patient preparation for risk assessment, and streamline cancer risk assessment pathways. With further refinement and testing in more diverse populations, it may facilitate earlier identification of individuals at increased cancer risk.

  • Open Access

    Fine-mapping of breast cancer susceptibility loci highlights critical methodological dependencies and the value of complementary approaches

    by Denise G. O’MAhony, Jonathan Beesley, Maria Zanti, Joe Dennis, Diptavo Dutta, Peter Kraft, Vessela N. Kristensen, Georgia Chenevix-Trench, Douglas F. Easton, Kyriaki Michailidou

  • Genetic and cellular architecture of breast cancer risk across ancestries

    by James L Li, Maria Zanti, Jacob Williams, Om Jahagirdar, Guochong Jia, Alistair Turcan, Qiang Hu, Jean-Tristan Brandenburg, Li Yan, Weang-Kee Ho, et al.

    Background: Breast cancer genome-wide association studies (GWAS) have identified more than 200 susceptibility loci, but most studies are dominated by European and East Asian populations. Methods: We analyzed breast cancer GWAS summary statistics from African (AFR), East Asian (EAS), European (EUR), and Hispanic/Latina (H/L) samples (159 297 cases and 212 102 controls). We estimated logit-scale SNP-based heritability, polygenicity, and cross-ancestry genetic correlation, partitioned heritability across functional annotations, and integrated GWAS results with the Tabula Sapiens single-cell atlas using scDRS+. Results: The logit-scale heritability of breast cancer ranged from h2 = 0.47 (SE = 0.07) in EAS to AFR h2 = 0.61 (SE = 0.10), with no significant differences across ancestries (P = .63). The model-implied number of non-null susceptibility SNPs in the sparse normal-mixture effect-size model also varied from 4446 (SE = 3100) in EAS to 8308 (SE = 2751) in AFR, but differences were not significant across ancestries (P = .55). Cross-sample genetic correlations varied, with the strongest correlation between EUR and EAS (ρ=0.79, SE = 0.08) and weakest between AFR and H/L (ρ=0.26, SE = 0.24). Regulatory annotations were enriched for breast cancer heritability across samples. Integration with single-cell expression profiles implicated ancestry-shared associations with innate immune, secretory epithelial, and stromal cell types. Conclusion: These results indicate substantial cross-ancestry sharing of breast cancer polygenic architecture, highlight a consistent contribution of regulatory variation, and identify convergent cellular contexts that motivate functional follow-up and inform expectations for the transferability and attainable performance of common-variant risk prediction across populations.

  • Open Access

    Priorities for breast cancer risk assessment in UK women under age 50: a survey and discrete choice experiment

    by Rebecca A. Dennison, Maria Valasaki, Stuart Wright, Reuben Frost, Sacha J. Howell, Antonis C. Antoniou, Douglas F. Easton, Stephen Morris, Montserrat Garcia-Closas, Victoria G. Woof, et al.

    Background: National guidelines recommend English women between 30 and 49 years with moderate/high risk of breast cancer (BC) be offered screening and prevention interventions. Identification largely relies on family history-based criteria amongst women self-presenting in primary care. We aimed to understand the preference for different potential risk assessment strategies in this population. Methods: A cross-sectional survey including a discrete choice experiment. Risk assessments were defined using six attributes, including initiation strategy, eligibility for a full/detailed risk assessment, components of the risk assessment, including multifactorial risk assessment based on the BOADICEA/CanRisk model, and sensitivity. Coefficients from conditional logistic regression were used to estimate preference for different risk assessment approaches compared to current care. Results: Participants ( n = 893) preferred alternative approaches for risk assessments over current care, particularly where all eligible women were proactively invited and more above-average risk women were correctly identified. All but one of 21 risk assessment approaches was preferred, with the most favoured approaches having a probability of being preferred over current care >92%. Education level and ethnicity potentially impacted the strength of participant priorities. Conclusions: Offering multifactorial BC risk assessments to younger women in primary care, especially the most proactive and broad approaches, would be acceptable and preferred over current practice.

  • Open Access

    Contribution of Risk Factors, Including Polygenic Score, to the Multifactorial Risk Assessment for the Implementation of Personalized Breast Cancer Screening: Insights from the PERSPECTIVE: Integration and Implementation Project

    by Xin Yang, Juliet A. Usher-Smith, Kristina M. Blackmore, Jennifer D. Brooks, Kathleen A. Bell, Tim Carver, Amy Chang, Jocelyne Chiquette, Douglas F. Easton, Andrea Eisen, et al.

    Background/Objectives: Risk-based breast cancer (BC) screening can provide tailored recommendations based on individual risk. We aimed to identify key predictors for BC risk stratification to inform implementation in screening programs. Methods: We estimated 10-year BC risks using BOADICEA v.6 (CanRisk) in 3753 women aged 40–70 with no cancer history from the PERSPECTIVE I&I cohort. The primary endpoint was risk reclassification, assessed as the proportion of women whose assigned 10-year risk category changed when using different risk factor combinations against a full multifactorial model including questionnaire-based risk factors (QRFs), polygenic score (PGS), mammographic density (MD), and pedigree-structured first- and second-degree family history (FH) of breast, ovarian, pancreatic and prostate cancer, including both affected and unaffected relatives. Relative risk thresholds were set as <1.5 (average), 1.5–2.7 (higher-than-average), and ≥2.7 (high), equivalent to the remaining lifetime risk categories of <15%, 15–25% and ≥25% for women aged 30 (the anchor) to age 80. We quantified individual-level reclassification flows by direction and magnitude. Results: Excluding PGS from risk calculations led to the highest overall reclassification. Using only the BC status in first- and second-degree relatives produced comparable risk classification to that of the full FH data that included breast, ovarian, prostate and pancreatic cancer (reclassification = 0.5%). However, collecting only affected relatives led to overestimation of risk. Excluding either PGS, MD or FH resulted in a greater proportion of reclassification among younger women. Adding the PGS to risk factors already collected in provincial screening programs reduced reclassification from 23% to ~13%. Conclusions: PGS, MD, QRFs and FH of BC in affected and unaffected first- and second-degree relatives are key for refining risk stratification. These findings provide real-world evidence on how incorporating different sets of risk factors, both those routinely collected in screening programs and those requiring additional data collection, affect individual-level risk classification amongst a population-based cohort, and how the impacts differ across age groups. While risk classification reflects model-based changes in estimated risk categories rather than direct evidence of mis-screening or clinical outcomes, comparison with the current eligibility criteria used to identify women at higher-than-average risk highlights the potential clinical value of a multifactorial risk assessment approach in ensuring more appropriate screening strategies.

  • Open Access

    Natural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis

    by Nasim Mavaddat, Daniel R. Barnes, Kyriaki Michailidou, Emily Zhao, Debra Frost, Goska Leslie, Joe Dennis, Qin Wang, Manjeet K. Bolla, Embrace, et al.

    Background: The influence of age at menarche (AAM) and age at natural menopause (ANM) on breast cancer (BC) risk in BRCA1 and BRCA2 germline pathogenic variant (PV) carriers is uncertain. Observational studies are prone to bias and have limited statistical power. Mendelian randomization (MR) minimises bias and may be used to examine causal effects. Methods: Two-sample and age-specific MR analyses for BC were performed. For AAM, two-sample multivariable MR and mediation analyses to account for the confounding effect of body mass index (BMI), were undertaken. Results: Genetic scores for ANM and AAM predicted the respective traits in PV carriers. Inverse-variance weighted hazard ratios (HR) for genetically predicted ANM per-year were HR = 0.99 (95%CI:0.97–1.01, p = 0.45) and HR = 1.04 (95% CI:1.01–1.06, p = 0.003) for BRCA1 and BRCA2 PV carriers, respectively. After adjusting for genetic associations with BMI, AAM per-year on BC risk were HR = 0.90 (95%CI:0.83–0.98, p = 0.01) and HR = 0.95 (95%CI:0.86–1.04, p = 0.26) for BRCA1 and BRCA2 carriers, respectively, consistent with a protective effect of later AAM. Discussion: MR analyses support causal associations between ANM and BC risk in BRCA2 , but not BRCA1 , and between AAM and BC risk in BRCA1 and BRCA2 PV carriers. These results may aid risk prediction models and genetic counselling of carriers.

  • Open Access

    A reanalysis of a genome-wide association study on breast cancer in Asian populations using the SG10K_Health reference panel for imputation: a multi-Centre case–control analysis

    by Xuling Chang, Shivaani Mariapun, Mengyu Li, Ling Wang, Peh Joo Ho, Alexis Jiaying Khng, Kenneth R Muir, Artitaya Lophatananon, Kristan J Aronson, Rachel A Murphy, et al.

    Genome-wide association studies (GWAS) have identified numerous genetic variants linked to breast cancer risk, but most discoveries come from European populations, limiting their applicability to other populations. Here, we show that the choice of genotype imputation reference panel, an essential step for GWAS, affects variant detection in Asian populations. Using two large breast cancer datasets from the Breast Cancer Association Consortium (n = 38 954 Asian samples), we compared the 1000 Genomes (1KG) reference panel with SG10K_Health (SG10K), an Asian-specific panel. SG10K imputed more rare variants and achieved higher accuracy for rare alleles (MAF < 0.001), while 1KG performed better for common variants in some contexts. Differences in panel performance influenced association signals, including breast cancer candidate loci such as FGFR2, TOX3, and ESR1. Together, these findings support the use of population-specific imputation panels as a means to improve variant discovery in underrepresented populations.

  • Open Access

    Modeling Individual-Level Uncertainty From Missing Data in Multifactorial Breast Cancer Risk Prediction

    by Bethan L. White, Lorenzo Ficorella, Xin Yang, Kamila Czene, Mikael Eriksson, Per Hall, Stephanie Archer, Marc Tischkowitz, Juliet A. Usher-Smith, Douglas F. Easton, et al.

    PURPOSE: Multifactorial breast cancer (BC) risk prediction models use a range of predictors to estimate an individual's chance of developing BC. Data on risk factors are often incomplete, and point estimates calculated when data are missing can mask considerable uncertainty. Quantifying this uncertainty is critical for effective risk communication. METHODS: We used Monte Carlo simulation methods to estimate the distribution of 10-year BC risk for individuals with missing data, using the BOADICEA multifactorial model as an example. Multivariate imputation by chained equations with large representative reference data sets was used to sample missing covariates. We developed a framework for estimating the uncertainty distribution, uncertainty intervals (UIs), and probability of reclassification, which can be applied to any given individual with missing risk factor data. This was applied to estimating individual-level uncertainty distributions and quantifying the probability of reclassification when groups of risk factors are measured, for a range of example women. RESULTS: Women with limited risk factor data had considerable uncertainty in their estimated BC risk, and 95% UIs spanned all risk categories. This was especially relevant for women classified as moderate-risk, such as those with strong family history or a moderate-risk pathogenic variant. Reclassification probability in this case was as high as 57.5%, with 95% UI of 0.9% to 9.3% for the 10-year risk from age 40 years. Risk certainty improved with additional data collection, particularly genetic information or mammographic density measurement. CONCLUSION: Our results demonstrate that, in some cases, there is considerable probability of reclassification after collecting missing data. Methodology presented here can identify situations where it would be most beneficial to collect additional information, to enable better informed clinical decision making.

  • Open Access

    Experimental Mis-Splicing Assessment and ACMG/AMP-Guided Classification of 47 ATM Splice-Site Variants

    by Inés Llinares-Burguet, Lara Sanoguera-Miralles, Elena Bueno-Martínez, Ada Esteban-Sanchez, Daniel Romano-Medina, Lobna Ramadane-Morchadi, Alicia García-Álvarez, Pedro Pérez-Segura, Doug F. Easton, Peter Devilee, et al.

    Pathogenic germline variants in the ATM gene are associated with a 20–30% lifetime risk of breast cancer. Crucially, a relevant fraction of loss-of-function variants in breast cancer susceptibility genes disrupts pre-mRNA splicing. We aimed to perform splicing analysis of ATM splice-site variants identified in the large-scale sequencing project BRIDGES (Breast Cancer After Diagnostic Gene Sequencing). To this end, we bioinformatically selected 47 splice-site variants across 17 exons that were genetically engineered into three minigenes and assayed in MCF-7 cells. Aberrant splicing was observed in 38 variants. Of these, 30 variants, including 7 missense, yielded no or negligible expression of the minigene full-length (mgFL) transcript. A total of 69 different transcripts were characterized, 48 of which harboured a premature termination codon. Some variants, such as c.2922-1G>A, generated complex patterns with up to 10 different transcripts. Alternative 3′ or 5′ splice-site usage was the predominant event. Integration of ATM minigene read-outs into the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)-based specifications for the ATM gene enabled the classification of 30 ATM variants as pathogenic or likely pathogenic and 9 as likely benign. Overall, splicing assays provide key information for variant interpretation and the clinical management of patients.


  • Open Access

    Supplementary Table S3 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model

    by Nasim Mavaddat, Lorenzo Ficorella, Tim Carver, Andrew Lee, Alex P. Cunningham, Michael Lush, Joe Dennis, Marc Tischkowitz, Kate Downes, Donglei Hu, et al.

    Supplementary Table S3 shows SNPs and weights for the BCAC PRS313.